Patents by Inventor Anja Geissler
Anja Geissler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200338069Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than. 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: July 14, 2020Publication date: October 29, 2020Applicant: GRÜNENTHAL GMBHInventors: KLAUS WENING, ANJA GEIßLER- FICHTNER, JANA DENKER, LUTZ BARNSCHEID
-
Publication number: 20200276188Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: May 11, 2020Publication date: September 3, 2020Applicant: Grünenthal GMBHInventors: KLAUS WENING, ANJA GEIßLER, JANA DENKER, LUTZ BARNSCHEID
-
Publication number: 20200268748Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: May 11, 2020Publication date: August 27, 2020Applicant: GRUNENTHAL GMBHInventors: Klaus WENING, ANJA GEISSLER-FICHTNER, JANA DENKER, LUTZ BARNSCHEID
-
Patent number: 10624862Abstract: The invention relates to a tamper-resistant, oral pharmaceutical dosage form comprising a pharmacologically active ingredient having psychotropic action and an ethylene-vinyl acetate (EVA) polymer which provides resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.Type: GrantFiled: July 10, 2014Date of Patent: April 21, 2020Assignee: GRÜNENTHAL GMBHInventors: Klaus Wening, Lutz Barnscheid, Sebastian Schwier, Anja Geißler
-
Publication number: 20200101020Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.Type: ApplicationFiled: December 3, 2019Publication date: April 2, 2020Applicant: GRÜNENTHAL GMBHInventors: Lutz BARNSCHEID, Eric GALIA, Sebastian SCHWIER, Ulrike BERTRAM, Anja GEISSLER, Kornelia GRIESSMANN, Johannes BARTHOLOMÄUS
-
Publication number: 20200038329Abstract: Thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, comprising an opioid (A), a free physiologically acceptable acid (B) in an amount of from 0.001 to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.Type: ApplicationFiled: October 15, 2019Publication date: February 6, 2020Applicant: GRÜNENTHAL GMBHInventors: Johannes BARTHOLOMÄUS, Anja Geissler, Ulrike BERTRAM, Kornelia GRIESSMANN, Fatima BICANE
-
Publication number: 20200030317Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur. The tamper-resistant pharmaceutical dosage form is useful in methods of treat diseases or disorders susceptible to the pharmacologically active compound; and in some embodiments discourages abuse in that when reduced to a powder the powdered dosage form exhibits a lower score for drug-liking than the pharmacologically active compound itself as assessed on a visual analog scale.Type: ApplicationFiled: September 27, 2019Publication date: January 30, 2020Applicant: GRÜNENTHAL GMBHInventors: KLAUS WENING, ANJA GEIßLER- FICHTNER, JANA DENKER, LUTZ BARNSCHEID
-
Publication number: 20200009055Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: July 19, 2019Publication date: January 9, 2020Applicant: GRÜNENTHAL GMBHInventors: KLAUS WENING, ANJA GEISSLER, JANA DENKER, LUTZ BARNSCHEID
-
Patent number: 10493033Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.Type: GrantFiled: February 21, 2018Date of Patent: December 3, 2019Assignee: GRÜNENTHAL GMBHInventors: Lutz Barnscheid, Eric Galia, Sebastian Schwier, Ulrike Bertram, Anja Geissler, Kornelia Griessmann, Johannes Bartholomäus
-
Publication number: 20190142757Abstract: The invention relates to a tamper-resistant pharmaceutical dosage form comprising one or more particles, wherein each of said one or more particles comprises a pharmacologically active ingredient and a physiologically acceptable polymer; has a breaking strength of at least 300 N; has a weight of at least 2 mg; and optionally, comprises a film-coating; wherein the total weight of the pharmaceutical dosage form is greater than the total weight of said one or more particles.Type: ApplicationFiled: November 9, 2018Publication date: May 16, 2019Applicant: GRÜNENTHAL GMBHInventors: LUTZ BARNSCHEID, ANJA GEIßLER, KLAUS WENING, JANA PÄTZ
-
Publication number: 20190111050Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: December 12, 2018Publication date: April 18, 2019Applicant: GRÜNENTHAL GMBHInventors: KLAUS WENING, ANJA GEIßLER- FICHTNER, JANA DENKER, LUTZ BARNSCHEID
-
Publication number: 20190054081Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: October 22, 2018Publication date: February 21, 2019Applicant: GRÜNENTHAL GMBHInventors: Klaus Wening, Anja Geissler-Fichtner, Jana Denker, Lutz Barnscheid
-
Publication number: 20180369237Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: August 29, 2018Publication date: December 27, 2018Applicant: GRÜNENTHAL GMBHInventors: Klaus WENING, ANJA GEIßLER, JANA DENKER, LUTZ BARNSCHEID
-
Publication number: 20180326067Abstract: A thermoformed, tamper-resistant pharmaceutical dosage form comprises: a) a pharmacologically active ingredient; b) a polyalkylene oxide having a weight average molecular weight of more than 200,000 g/mol; and c) a zinc component, wherein the content of said zinc component is at least 1 ppm, relative to the total weight of the pharmaceutical dosage form. When the pharmacologically active ingredient is effective against pain, the pharmaceutical dosage form may be used in a method of treating pain. When the pharmacologically active ingredient has abuse potential, the pharmaceutical dosage form may be used in a method of reducing the incidence of the abuse of said pharmacologically active ingredient.Type: ApplicationFiled: July 20, 2018Publication date: November 15, 2018Applicant: GRÜNENTHAL GMBHInventors: LUTZ BARNSCHEID, ERIC GALIA, ANJA GEIßLER, JANA PÄTZ, SEBASTIAN SCHWIER, JULIA BARONSKY-PROBST
-
Patent number: 10064945Abstract: A thermoformed, tamper-resistant pharmaceutical dosage form comprises: a) a pharmacologically active ingredient; b) a polyalkylene oxide having a weight average molecular weight of more than 200,000 g/mol; and c) a zinc component, wherein the content of said zinc component is at least 1 ppm, relative to the total weight of the pharmaceutical dosage form. When the pharmacologically active ingredient is effective against pain, the pharmaceutical dosage form may be used in a method of treating pain. When the pharmacologically active ingredient has abuse potential, the pharmaceutical dosage form may be used in a method of reducing the incidence of the abuse of said pharmacologically active ingredient.Type: GrantFiled: May 10, 2013Date of Patent: September 4, 2018Assignee: GRUENENTHAL GMBHInventors: Lutz Barnscheid, Eric Galia, Anja Geißler, Jana Pätz, Sebastian Schwier, Julia Baronsky-Probst
-
Publication number: 20180221307Abstract: The invention relates to a monolithic pharmaceutical dosage form comprising a hot melt-extruded first segment (S1) and a second segment (S2); wherein the first segment (S1) contains at least a first pharmacologically active ingredient (A1) and/or the second segment (S2) contains at least a second pharmacologically active ingredient (A2); and the segment (S1) and/or the segment (S2) is tamper-resistant and/or exhibits a breaking strength of at least 300 N.Type: ApplicationFiled: January 30, 2018Publication date: August 9, 2018Applicant: GRÜNENTHAL GMBHInventors: ANJA GEIßLER-FICHTNER, Klaus Wening, Lutz Barnscheid, Jana Pätz
-
Publication number: 20180177732Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.Type: ApplicationFiled: February 21, 2018Publication date: June 28, 2018Applicant: GRÜNENTHAL GMBHInventors: Lutz BARNSCHEID, Eric GALIA, Sebastian SCHWIER, Ulrike BERTRAM, Anja GEISSLER, Kornelia GRIESSMANN, Johannes BARTHOLOMÄUS
-
Patent number: 9925146Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.Type: GrantFiled: September 1, 2015Date of Patent: March 27, 2018Assignee: GRÜNENTHAL GMBHInventors: Lutz Barnscheid, Eric Galia, Sebastian Schwier, Ulrike Bertram, Anja Geissler, Kornelia Griessmann, Johannes Bartholomäus
-
Publication number: 20180078544Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: November 28, 2017Publication date: March 22, 2018Applicant: GRÜNENTHAL GMBHInventors: KLAUS WENING, ANJA GEIßLER, JANA DENKER, LUTZ BARNSCHEID
-
Publication number: 20180044347Abstract: Crystalline salts of 4,5 ?-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) (hydrocodone bitartrate) are disclosed and three polymorphic forms of these salts are reported. The invention further relates to a pharmaceutical composition comprising such a salt and such a salt as a medicament and for the treatment and/or prevention of pain.Type: ApplicationFiled: October 24, 2017Publication date: February 15, 2018Applicant: GRÜNENTHAL GMBHInventors: Klaus WENING, Lutz BARNSCHEID, Anja GEISSLER, Jana DENKER, Dagmar LISCHKE